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Abstract
Background: Vision loss due to diabetic retinopathy can largely be prevented or delayed through treatment.
Patients with vision-threatening diabetic retinopathy are typically offered laser or intravitreal injections which often
require more than one treatment cycle. However, treatment is not always initiated, or it is not completed, resulting
in poor visual outcomes. Interventions aimed at improving the uptake or completion of treatment for diabetic
retinopathy can potentially help prevent or delay visual loss in people with diabetes.
Methods: We will search MEDLINE, Embase, Global Health and Cochrane Register of Studies for studies reporting
interventions to improve the uptake of treatment for diabetic retinopathy (DR) and/or diabetic macular oedema
(DMO), compared with usual care, in adults with diabetes. The review will include studies published in the last 20
years in the English language. We will include any study design that measured any of the following outcomes in
relation to treatment uptake and completion for DR and/or DMO: (1) proportion of patients initiating treatment for
DR and/or DMO among those to whom it is recommended, (2) proportion of patients completing treatment for DR
and/or DMO among those to whom it is recommended, (3) proportion of patients completing treatment for DR
and/or DMO among those initiating treatment and (4) number and proportion of DR and/or DMO rounds of
treatment completed per patient, as dictated by the treatment protocol. For included studies, we will also report
any measures of cost-effectiveness when available. Two reviewers will screen search results independently. Risk of
bias assessment will be done by two reviewers, and data extraction will be done by one reviewer with verification
of 10% of the papers by a second reviewer. The results will be synthesised narratively.
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Discussion: This rapid review aims to identify and synthesise the peer-reviewed literature on the effectiveness of
interventions to increase uptake and completion of treatment for DR and/or DMO in LMICs. The rapid review
methodology was chosen in order to rapidly synthesise the available evidence to support programme
implementers and policy-makers in designing evidence-based health programmes and public health policy and
inform the allocation of resources.
Systematic review registration: OSF osf.io/h5wgr
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Background
Vision loss due to diabetic retinopathy (DR) can largely
be prevented or delayed through treatment. DR pro-
grammes focus on regular screening of people living
with diabetes and referral to eye care services for further
assessment. Patients with vision-threatening diabetic ret-
inopathy (VTDR), including proliferative diabetic retin-
opathy (PDR) and/or diabetic macular oedema (DMO),
are then offered laser treatment and/or intravitreal injec-
tions which often require more than one treatment visit
[1, 2]. However, the effectiveness of DR treatment is
dependent on the timely initiation and completion of
the prescribed treatment course.
Different factors—both from the demand and the sup-
ply side—can affect treatment uptake and completion
[3]. Health systems in low- and middle-income country
(LMIC) settings experience limitations in the delivery of
high-quality and timely DR treatment, including low
numbers of ophthalmologists trained in DR manage-
ment, inadequate referral systems, limited access to
technology and equipment and the lack of health infor-
mation systems and policies that address DR manage-
ment [4, 5]. LMIC populations have competing health
needs that determine their priorities and health-seeking
behaviours in relation to eye health. Barriers like fear,
price of services, waiting times or distance can lead to
patients missing treatment, or initiating treatment but
not completing it, resulting in poor visual outcomes.
Low uptake of DR treatment compounds the challenge
to prevent visual loss in people with diabetes and wastes
resources in already limited health systems [6]. Interven-
tions aiming to improve uptake and completion of DR
treatment need to target the relevant factors in the
healthcare environment in which the patients are to re-
ceive treatment [6].
Access to DR services is a widespread problem in
LMICs. Studies of DR services in Pakistan, Oman and
China reported that 29.5%, 22.8% and 27.9% of patients
respectively did not initiate treatment [7–9]. In the study
in China, an additional 17.6% did not complete the treat-
ment course, for reasons including being unaware of the
importance of treatment and the need to complete the
full course, and fear of treatment [9]. In high-income
countries, the proportion of patients not completing
treatment tends to be lower than in low-income coun-
tries but still significant. A review in the USA reported
that approximately 15% of patients did not initiate treat-
ment and 15% of those did not complete it [10].
Laser photocoagulation is a highly effective treatment
for PDR and DMO [11–13]. DMO and PDR can be
treated with anti-vascular endothelial growth factor
(VEGF) via intravitreal injections [14, 15]. Intravitreal
steroids, while not indicated as first-line therapy for
most eyes with DMO, have been used by some clinicians
for eyes that do not adequately respond to anti-VEGF
therapy [16, 17]. Anti-VEGF is also indicated in age-
related macular degeneration (ARMD) [18]. However,
there is evidence that the uptake of anti-VEGF by pa-
tients with DMO is significantly lower compared to pa-
tients with ARMD [19–21]. People with diabetes often
have other co-morbidities that increase their need to at-
tend hospital appointments, so completing an anti-
VEGF treatment regime can be a significant additional
burden. Patients receiving intravitreal injections report
high levels of anxiety and significant psychological im-
pact [22]. The dependence on a caregiver to accompany
the patient and the financial cost of treatment also pose
a burden on the patient [23, 24].
This rapid review aims to identify and summarise the
most recent information on the effectiveness of interven-
tions to increase uptake and completion of treatment for
DR and/or DMO in LMICs.
Methods
Rapid review question
What interventions are effective in increasing uptake
and completion of treatment for DR and/or DMO
among people with diabetes in LMICs?
Protocol and registration
We used the STARR Decision Tool and the WHO prac-
tical guide to carefully consider the methods most ap-
propriate for this rapid review and the possible
limitations introduced by those methods [25, 26].
Bascaran et al. Systematic Reviews           (2021) 10:27 Page 2 of 5
Additional file 1 provides the adapted Preferred
Reporting Items for Systematic Reviews and Meta-
analysis Protocols (PRISMA-P) which is used to report
this protocol.
The protocol was registered on the Open Science
Framework (OSF): osf.io/h5wgr; more details are pro-
vided in Additional file 2. Any protocol amendments will
be documented in the registration site [27].
Eligibility criteria
We will limit the search to peer-reviewed publications of
studies conducted in LMICs in any setting in the last 20
years (i.e. community or facility based), which examine
the uptake and/or completion of treatment prescribed
for DR or DMO. We defined LMICs according to the
World Bank Classification for 2019. Studies will only be
included if they report at least one of the first four out-
comes. We will restrict to publications in the English
language. We will only include studies where a full-text
report is available (Table 1).
Information sources
We will search MEDLINE, Embase, Global Health and
the Cochrane Register of Studies. The search strategies
will be developed by a Cochrane Eyes and Vision Infor-
mation Specialist (IG). We will search the reference lists
of included studies. Grey literature will not be
considered.
Search strategy
The search strategy is included in Additional file 3.
Data management and selection process
Screening will be done using online review manage-
ment software (Covidence, Veritas Health Innovation,
Melbourne, Australia; available at www.covidence.org).
Each title and abstract will be screened independently
by two reviewers. Disagreements will be resolved by
discussion. Full-text articles describing potentially
relevant studies will be screened by two reviewers in-
dependently against the inclusion and exclusion cri-
teria and any differences resolved by consensus. A
PRISMA flow diagram will be completed to summar-
ise the study selection process.
Risk of bias assessment
Risk of bias will be assessed by two reviewers independ-
ently using SIGN critical appraisal checklists for this
purpose, available at https://www.sign.ac.uk. Any differ-
ences will be agreed by consensus, and a third researcher
will be consulted if any differences are unresolved. The
overall risk of bias for included studies will be reported
in narrative form and used to interpret the findings of
the review.
Data extraction
A custom-designed Excel data extraction form will be
piloted by two reviewers on 3 papers and adapted ac-
cordingly. Data will be extracted by one reviewer, and
the accuracy of data extraction will be checked by a sec-
ond reviewer for 10% of studies. If there are significant
data extraction errors (for example, important errors in
more than 1% of records), then a further set of records
will be checked. The following data items will be col-
lected for each identified intervention (Table 2).
Data synthesis
We anticipate that there will be clinical and methodo-
logical diversity in the studies that we find, so we plan to
summarise the data narratively, following SWiM report-
ing guidance: Synthesis Without Meta-analysis [28].
We will report outcomes in terms of proportions in
intervention and comparator groups and will calculate
the risk ratio with 95% confidence intervals as the main
measure of effect, but this will be dependent on how the
data are reported by the included studies. In observa-
tional studies, for example, adjusted odds ratios may be
the most appropriate measure of effect. We will present
key characteristics such as study design, sample size and
risk of bias in tables and use visual displays for effect es-
timates when possible. We will consider heterogeneity
by examining study design, geographical location, demo-
graphic characteristics such as age and sex as well as the
nature of the interventions and the settings in which
Table 1 Eligibility criteria
Population Adults (aged ≥ 18 years) with type 1 or type 2 diabetes in LMICs who have been identified as needing treatment for DR and/or DMO
Intervention Any intervention that seeks to increase uptake and/or completion of treatment for DR and/or DMO among adults with diabetes
Comparator Usual care or another intervention seeking to increase uptake and/or completion of treatment for DR and/or DMO
Outcomes 1. Proportion of patients initiating treatment for DR and/or DMO among those to whom it is recommended
2. Proportion of patients completing treatment for DR and/or DMO among those to whom it is recommended
3. Proportion of patients completing treatment for DR and/or DMO among those initiating treatment
4. Number and proportion of DR and/or DMO rounds of treatment completed per patient, as dictated by the treatment protocol
5. Cost-effectiveness of intervention to increase DR/DMO treatment uptake or completion
Study design Any interventional or observational comparative study
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they have been applied. If sufficient data are available,
we will calculate I2 which is a measure of the percentage
of variation across studies that is due to heterogeneity
rather than chance. We will use the GRADE approach,
as applied to narrative syntheses, to assess the certainty
of the synthesis findings [29].
Depending on the findings, we will group studies by
setting, intervention target (patients, health providers,
health system), type of intervention, study design and
outcomes. For each comparison and outcome, we will
provide a description of the findings alongside the cer-
tainty of the evidence, ensuring consistency with the re-
view question and providing a judgement as to the
extent to which the studies contribute to the synthesis.
Discussion
This rapid review aims to identify and synthesise the
peer-reviewed literature on the effectiveness of interven-
tions to increase uptake and completion of treatment for
DR and/or DMO in LMICs. The rapid review method-
ology was chosen in order to rapidly synthesise the avail-
able evidence to support programme implementers and
policy-makers in designing evidence-based health pro-
grammes and public health policy and inform the alloca-
tion of resources. This review may also identify gaps in
the evidence that could inform further research priorities
related to the management of diabetic retinopathy in
LMICs.
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Additional file 1:. Reporting standards – PRISMA-P Checklist.
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Additional file 3:. Search strategy.
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Authors, title, publication date, journal citation
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Intervention target: patients, providers, policy-makers
Treatment indication: pan retinal laser photocoagulation (PRP) for PDR, focal laser, intravitreal anti-VEGF or steroids for DMO
Treatment completion guideline, e.g. number of laser sessions, number of burns and number of injections
Type of intervention, e.g. guidelines, treatment regime, educational programmes, financial subsidies, follow-up prompts and
reminders, ongoing quality assurance and improvement processes, electronic patient management
Factors associated with uptake/completion of treatment: provider and patient
Outcomes Proportion of patients initiating treatment for DR and/or DMO among those to whom it is recommended
Proportion of patients completing treatment for DR and/or DMO among those to whom it is recommended
Proportion of patients completing treatment for DR and/or DMO among those initiating treatment
Number and proportion of DR and/or DMO rounds from the recommended treatment protocol completed per patient
Cost-effectiveness of intervention to increase DR/DMO treatment uptake or completion
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